ABSTRACT
Taleum inhalation aerosol, produced by EGIS Pharmaceuticals Works, was examined in an 8-week open cross-over self-controlled study in 50 patients suffering from extrinsic bronchial asthma. Intal powder capsule inhaled with the aid of a spinhaler was used as a reference drug. Changes in subjective complaints and symptoms were continuously recorded on a score scale in the patients' diary. The alterations in respiratory parameters were measured. Laboratory parameters were monitored. On the basis of the results Taleum spray was found to be effective in the prevention of bronchial asthma. It proved to be a well tolerated drug form of simple use.
Subject(s)
Asthma/drug therapy , Cromolyn Sodium/therapeutic use , Hypersensitivity/complications , Administration, Inhalation , Adolescent , Adult , Aerosols , Airway Resistance/drug effects , Asthma/diagnosis , Asthma/etiology , Asthma/physiopathology , Cromolyn Sodium/pharmacology , Female , Forced Expiratory Volume/drug effects , Humans , Male , Peak Expiratory Flow Rate/drug effects , Vital Capacity/drug effectsABSTRACT
Paxirasol aerosol applied in daily 3 x 5 puff doses in the treatment of silicosis patients is found to be a well tolerated drug form. In the course of the 21-day therapy especially coughing and chest pain were moderated, but the product also controlled, the catarrhal coat formation on the mucosa. It influenced abundant expectoration and dispnoea beneficially. During the therapy the laboratory parameters did not change. The objective respiratory parameters improved but the change was non-significant. Paxirasol aerosol is found useful in the treatment of chronic bronchitis accompanying silicosis. Evaluable side-effects were not registered.